AMENDED CLAIM SET:

1. (currently amended) A 1,4-diazabicycloalkane ~~derivative of Formula I~~ compound of Formula IV:





any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof,

wherein

n is 1, 2 or 3;

X represents O or S ~~O, S or Se~~; and

Ar represents ~~a carbocyclic aromatic (aryl) group~~ an aryl group selected from phenyl and naphthyl, or a ~~heterocyclic aromatic (heteroaryl) group~~ heteroaryl group selected from furanyl, thienyl and pyridinyl, which aromatic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, alkenyl, alkynyl, alkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halogen, CF_3, CN, NO_2, NH_2, carboxy, carbamoyl, amido, sulfamoyl, phenyl and benzyl.

2. (currently amended) The compound of claim 1, wherein Ar ~~represents a carbocyclic aromatic (aryl) group, or a heterocyclic aromatic (heteroaryl) group, which aromatic group~~ may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, alkoxy, halogen, CF_3, CN, NO_2, NH_2 and phenyl.

3. – 6. (cancelled).

7. (currently amended) The compound of claim 1 [[6]], wherein ~~the carbocyclic aromatic group is~~ Ar represents phenyl, optionally substituted one or two times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cycloalkoxy, halogen, CF_3, CN, NO_2, NH_2, carboxy, carbamoyl, amido and sulfamoyl.

8. (cancelled).

9. (currently amended) The compound of claim 1 [[5]], which is

4-(5-Phenyl-1,3,4-oxadiazol-2-yl)-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(3-Methoxyphenyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(4-Methoxyphenyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(4-Chlorophenyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(4-Phenyl-phenyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane; ~~or~~

4-[5-(2-Naphthyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(2-Furyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(3-Pyridyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(4-Pyridyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane; or

4-[5-(2-Thienyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

or an enantiomer or a mixture of enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof.

10. – 22. (cancelled).

23. (previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, together with at least one pharmaceutically-acceptable carrier or diluent.

24. (currently amended) A method of the treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disease or disorder is associated with withdrawal symptoms caused by termination of use of tobacco, heroin, cocaine, morphine, benzodiazepines, benzodiazepine-like drugs, or alcohol ~~responsive to modulation of cholinergic receptors and/or monoamine receptors~~, which method comprises the step of administering to such a living animal body, including a human, in need thereof a therapeutically effective amount of a compound of claim 1, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof.

25. – 32. (cancelled).

33. (cancelled).

34. (new) The 1.4-diazabicycloalkane derivative of claim 1, wherein Ar represents phenyl, optionally substituted one or two times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cycloalkoxy, halogen, CF_3, CN, NO_2, NH_2, carboxy, carbamoyl, amido, sulfamoyl, phenyl, and benzyl.

35. (new) The 1.4-diazabicycloalkane derivative of claim 34, wherein Ar represents phenyl, optionally substituted one or two times with substituents selected from the group consisting of alkyl, alkoxy, halogen, CF_3, CN, NO_2, NH_2, and phenyl.